Error loading player: No playable sources found

89826

Plenary Session 5 - Stem Cell-derived Medicinal Products

Date
June 12, 2024
This product is not available for individual purchase, but it is available as part of the following products:

Stem cell-derived medicines have seen somewhat of a renaissance over the last year, following a difficult period in terms of regulatory approval. New stem cell therapies, including many iPSC-based therapies, are now under development for a variety of indications and more traditional regenerative approaches have seen regulatory approval. Despite this, there remain difficult challenges for stem cell-derived products, including product characterization and potency assay development for mechanisms of action that often must be postulated fairly widely.  

This session will present case studies by stakeholders that are successfully navigating this field, together with viewpoints from regulators.  


Speaker:


Releasing Criteria and Potency Assay Development of an iPSC-Derived Neural Progenitor Cell Product Targeting CNS Diseases

Jing Fan, Hopstem Biotechnology Inc.


Navigating the Regulatory Path: Clinical Translation of iPSCs 

Saravanan Karumbayaram, CBER, FDA


Cellular Engineering to Address Manufacturing and Regulatory Concerns

Todd McDevittGenentech, a Member of the Roche Group



Panelist:


Andreea Barbu, Swedish Medical Products Agency


Related Products

Thumbnail for Plenary Session 7 - Streamlining AAV Vector-based Gene Therapy Development Through the Utilization of Manufacturing and Analytical Platform Approaches
Plenary Session 7 - Streamlining AAV Vector-based Gene Therapy Development Through the Utilization of Manufacturing and Analytical Platform Approaches
Our ability to treat diseases previously untreatable through the delivery of adeno-associated virus (AAV)-based gene therapies has been a tremendous advancement in pharmaceutical development…
Thumbnail for Parallel Session 2 - How to Control Off Target Genotoxicity for Genome and Epigenome Editing Medicines
Parallel Session 2 - How to Control Off Target Genotoxicity for Genome and Epigenome Editing Medicines
Genome editing is a tool that enables a new generation of medicines by directly targeting with high precision the genetic cause of a disease. It also allows for immune evasion and prevents microenvironment responses: concepts vital to more potent, off the shelf, cell, and gene therapies…
Thumbnail for Hot Topic Session - ICH Cell & Gene Therapy Discussion Group Updates
Hot Topic Session - ICH Cell & Gene Therapy Discussion Group Updates
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) brings together regulatory authorities and representatives from the pharmaceutical industry from across the globe to discuss a range of technical and scientific considerations for medicinal…